Navigation Links
Jefferson researchers identify critical marker of response to gemcitabine in pancreatic cancer
Date:6/4/2009

(PHILADELPHIA) A protein related to aggressive cancers can actually improve the efficacy of gemcitabine at treating pancreatic cancer, according to a Priority Report in Cancer Research, published by researchers at Thomas Jefferson University.

The protein, called Hu antigen R (HuR), is a stress response protein found in the cytoplasm of pancreatic tumor cells. In certain experimental settings, pancreatic cancer cells that overexpressed HuR were up to 30-fold more sensitive to gemcitabine (Gemzar), according to Jonathan Brody, Ph.D., assistant professor of Surgery at Jefferson Medical College of Thomas Jefferson University.

In a clinical correlate study that included 32 resected pancreatic cancer patients who received gemcitabine, patients who had low cytoplasmic HuR levels had a 7-fold increased mortality risk compared to patients with high levels. This was after adjustment for other variables including age, sex, radiation therapy and other chemotherapy use.

"This marker appears to tell us upfront whether a patient will respond to treatment with gemcitabine, which is the routine treatment for pancreatic cancer," said Dr. Brody, who is the senior author of the study. "Of course, larger and comprehensive prospective studies need to be performed, but we now have a real clue about how to make this treatment better. Finding a mechanism that regulates gemcitabine's metabolism in pancreatic cancer cells is the real novel and exciting aspect of these findings."

Dr. Brody and colleagues found that in pancreatic cancer, HuR helps to regulate an enzyme called deoxycytidine kinase (dCK), which is responsible for metabolizing and activating gemcitabine. As with most chemotherapy drugs, gemcitabine causes cell stress and activates the HuR stress proteins. In turn, the high levels of HuR stimulate the production of more dCK, thus making gemcitabine more efficient, according to Dr. Brody.

"Normally, patients higher HuR cytoplasmic levels have a worse prognosis, since HuR expression is associated with advanced malignancies," Dr. Brody said. "However, in our study, they did better than patients with low HuR levels when they were treated with gemcitabine. We think it's because they already have high HuR levels at the time of treatment, which may be a response to the tumor cell environment."

According to Dr. Brody, research is underway to find a way to activate HuR in patients with a low expression. Other goals include expanding these findings to a larger pancreatic cancer population, and to other tumors that may be treated with gemcitabine, including breast, ovarian and certain lung cancers. They also want to determine if other chemotherapeutic agents engage this intriguing and manipulative pathway.


'/>"/>

Contact: Emily Shafer
emily.shafer@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
2. Jefferson immunology researchers halt lethal rabies infection in brain
3. Jefferson radiation oncologists use real-time system to plant seeds against cancer
4. Jefferson researchers find personalized interventions key to improving colon cancer screening rates
5. Jefferson researchers uncover new evidence of prolactins possible role in breast cancer
6. MicroRNAs may be key to HIVs ability to hide, evade drugs, Jefferson scientists find
7. Jefferson scientists find protein may be key in developing deadly form of pancreatic cancer
8. Jefferson oncologists show focused radiation is effective as surgery against nerve tumor
9. Jefferson researchers find stem cells in degenerating spinal discs, potential for repair
10. Jefferson researchers show chemotherapy and radiation together extend lung cancer patients lives
11. Jefferson neuroscientists show anti-inflammation molecule helps fight MS-like disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... , ... July 24, 2017 ... ... Director,      (407) 916-7235, kklaproth(at)robinsmorton(dot)com , Robins & Morton, Perkins ... to celebrate the structural topping out of the new Destination Medical Building ...
(Date:7/24/2017)... , ... July 24, 2017 , ... SignatureCare Emergency ... will be awarded for the fall semester to a deserving student. Get your ... Spring 2017 scholarship was awarded to Mariana Castillo who is a nursing student at ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... Abuse and Mental Health Services Administration’s (SAMHSA) State Targeted Response to the Opioid ... Health Care Services, will facilitate the development of a hub and spoke model ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... effectively destroyed the construction site and threatened numerous homes and businesses nearby, causing ... article on NBCLosAngeles.com. Los Angeles Area consulting firm Fire Protection Group, Inc. ...
(Date:7/24/2017)... ... July 24, 2017 , ... The International Essential Tremor Foundation (IETF) will ... essential tremor (ET). The seminar will take place on Saturday, Aug. 26 at the ... The program will run from 9 a.m. to 12 p.m., with check-in beginning at ...
Breaking Medicine News(10 mins):
(Date:7/25/2017)... Massachusetts , July 25, 2017 The med-tech ... rare nervous system diseases, has concluded a worldwide license agreement ... drug SOM0226 against transthyretin amyloidosis (ATTR). Before this licensing agreement ... a Phase 2 study conducted in Europe ... the United States ...
(Date:7/24/2017)... , July 24, 2017  Diplomat Pharmacy, Inc. (NYSE: ... release its second quarter 2017 operating results on Monday, ... call to follow at 5:00 p.m. ET. ... listen to a live broadcast of the conference call ... referencing participant code 51641230 approximately 15 minutes prior to ...
(Date:7/21/2017)... International plc (NASDAQ: ENDP ) today announced ... network, the Company will be ceasing operations and closing ... Alabama . The closure of the facilities is ... 18 months. The Huntsville location ... and these restructuring actions are intended to better match ...
Breaking Medicine Technology: